{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maridebart+cafraglutide", "query": { "intervention": "Maridebart cafraglutide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maridebart+cafraglutide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T12:31:22.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07523711", "title": "Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "COC", "type": "DRUG" }, { "name": "Maridebart Cafraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "45 Years to 65 Years · Female only" }, "enrollment_count": 49, "start_date": "2026-04-09", "completion_date": "2026-11-18", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 2, "location_summary": "Dallas, Texas • Madison, Wisconsin", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07523711" }, { "nct_id": "NCT07429045", "title": "A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overweight and Obesity" ], "interventions": [ { "name": "AMG 133", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2025-03-11", "completion_date": "2025-11-21", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 5, "location_summary": "Lake Forest, California • Miami, Florida • Miami Lakes, Florida + 1 more", "locations": [ { "city": "Lake Forest", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07429045" }, { "nct_id": "NCT07684235", "title": "Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Maridebart cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 3200, "start_date": "2026-07-23", "completion_date": "2028-03-19", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 70, "location_summary": "Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07684235" }, { "nct_id": "NCT04478708", "title": "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "maridebart cafraglutide", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 110, "start_date": "2020-08-07", "completion_date": "2022-11-18", "has_results": true, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 3, "location_summary": "Anaheim, California • Tustin, California • Miami, Florida", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478708" }, { "nct_id": "NCT06858878", "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight" ], "interventions": [ { "name": "Maridebart cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1105, "start_date": "2025-03-17", "completion_date": "2027-04-16", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 59, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06858878" }, { "nct_id": "NCT07226778", "title": "Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 348, "start_date": "2025-10-10", "completion_date": "2026-05-28", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 4, "location_summary": "Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226778" }, { "nct_id": "NCT07229157", "title": "Effect of Maridebart Cafraglutide on the Heart's Electrical Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo for Maridebart Cafraglutide", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 81, "start_date": "2025-10-22", "completion_date": "2026-08-26", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07229157" }, { "nct_id": "NCT07575399", "title": "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity or Overweight" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 300, "start_date": "2026-05-11", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 44, "location_summary": "Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 38 more", "locations": [ { "city": "Pelham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07575399" }, { "nct_id": "NCT06660173", "title": "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus (T2DM)" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2024-11-07", "completion_date": "2026-11-10", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Lake Forest", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660173" }, { "nct_id": "NCT06858839", "title": "Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 3853, "start_date": "2025-03-12", "completion_date": "2027-04-16", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-11T12:31:22.721Z", "location_count": 74, "location_summary": "Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 59 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06858839" } ] }